CN1732962A - Process for preparing nanometer particle of adriacin-PACA-PBCA - Google Patents

Process for preparing nanometer particle of adriacin-PACA-PBCA Download PDF

Info

Publication number
CN1732962A
CN1732962A CNA2004100466489A CN200410046648A CN1732962A CN 1732962 A CN1732962 A CN 1732962A CN A2004100466489 A CNA2004100466489 A CN A2004100466489A CN 200410046648 A CN200410046648 A CN 200410046648A CN 1732962 A CN1732962 A CN 1732962A
Authority
CN
China
Prior art keywords
add
stir
pbca
alpha
dextran70
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004100466489A
Other languages
Chinese (zh)
Inventor
张阳德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CNA2004100466489A priority Critical patent/CN1732962A/en
Priority to PCT/CN2005/001056 priority patent/WO2006015534A1/en
Publication of CN1732962A publication Critical patent/CN1732962A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides a process for preparing nanometer particle of adriacin-PACA-PBCA, which comprises, reacting HCl solution with doxorubicin hydrochloride powder, stirring to dissolve, charging Dextran70 and charging alpha-butylcyanoacrylate, stirring and adjusting pH to be 7, passing through 0.45um filtration film and drying.

Description

The preparation method of amycin-paracyanogen base NBCA nanoparticle
Technical field
The present invention relates to a kind of preparation method to the cancer treatment drug nano-particle.
Technical background
Hepatocarcinoma is one of modal malignant tumor in the world, and at present, it is main comprehensive therapeutic plan that treatment hepatocarcinoma is still taked excision clinically, and many cases still need be accepted chemotherapy.But the toxicity of chemotherapy makes liver function and the out of condition person of whole body lose smelting and treats chance.In recent years, produce and developed the gene smelting and treat, but the prerequisite that the effective gene smelting is treated is nucleic acid molecules effectively must be delivered in the target cell.
Summary of the invention
Purpose of the present invention is that a kind of preparation method with amycin-paracyanogen base NBCA nanoparticle (DOX-PBCA-NP) of stronger targeting will be provided.
The preparation method of DOX-PBCA-NP of the present invention is: with HCl solution and the effect of doxorubicin hydrochloride powder, stir and make its dissolving, add Dextran again 70, add the positive fourth fat of alpha-cyanoacrylate, stir and wait to occur orange-yellow opalescence, regulate PH=7, cross 0.45 μ m filter membrane, drying promptly makes the present invention.
DOX-PBCA-NP with the present invention's acquisition, can deliver the multiple medicine that comprises chemotherapeutics, genomic medicine, its Targeting Performance significantly reduces the toxicity of chemotherapeutics, improve curative effect, can reduce drug dose and medication number of times, improve patient's compliance, improve the stability of genomic medicine ribozyme, prolong biological half-life, improve drug level and action time in the born of the same parents.
The specific embodiment
Specifically introduce the present invention below in conjunction with embodiment.
Get 0.1N HCl solution 50ml with pipet and place conical flask, add the doxorubicin hydrochloride powder 10mg that is dried to constant weight, stir and make its dissolving, the reuse micropipettor adds 1.5%Dextran 700.3ml, under the magnetic stirring apparatus effect, slowly add the positive fourth fat of alpha-cyanoacrylate 0.2ml, stir while dripping, be controlled at and added in 10 minutes.Seal a bottle, continue to stir 1000rpm 3h, wait to occur orange-yellow opalescence, regulate PH=7, cross 0.45 μ m filter membrane with 0.2NNaOH solution.Filtrate in vacuum drying oven 25 ℃ ,-dry under the 0.1kPa condition, promptly make the present invention.

Claims (2)

1, the preparation method of a kind of amycin-paracyanogen base NBCA nanoparticle, the steps include: with HCl solution and the effect of doxorubicin hydrochloride powder, stirring makes its dissolving, add Dextran70 again, add the positive fourth fat of alpha-cyanoacrylate, stir and wait to occur orange-yellow opalescence, regulate PH=7, cross 0.45 μ m filter membrane, drying promptly makes the present invention.
2, press the preparation method of the described amycin of claim 1-paracyanogen base NBCA nanoparticle, a DOX-PBCA-NP is got in making and settlement, the steps include: that getting 0.1N HCl solution 50ml with pipet places conical flask, add the doxorubicin hydrochloride powder 10mg that is dried to constant weight, stirring makes its dissolving, the reuse micropipettor adds 1.5%Dextran70 0.3ml, under the magnetic stirring apparatus effect, slowly add the positive fourth fat of alpha-cyanoacrylate 0.2ml, stir while dripping, be controlled at and added in 10 minutes; Seal a bottle, continue to stir 1000rpm3h, wait to occur orange-yellow opalescence, regulate PH=7, cross 0.45 μ m filter membrane with 0.2N NaOH solution, filtrate in vacuum drying oven 25 ℃ ,-dry under the 0.1kPa condition, promptly make the present invention.
CNA2004100466489A 2004-08-11 2004-08-11 Process for preparing nanometer particle of adriacin-PACA-PBCA Pending CN1732962A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CNA2004100466489A CN1732962A (en) 2004-08-11 2004-08-11 Process for preparing nanometer particle of adriacin-PACA-PBCA
PCT/CN2005/001056 WO2006015534A1 (en) 2004-08-11 2005-07-18 The preparation method of doxorubicin-polybutylcyanoacrylate nanoparticles

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNA2004100466489A CN1732962A (en) 2004-08-11 2004-08-11 Process for preparing nanometer particle of adriacin-PACA-PBCA

Publications (1)

Publication Number Publication Date
CN1732962A true CN1732962A (en) 2006-02-15

Family

ID=35839132

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004100466489A Pending CN1732962A (en) 2004-08-11 2004-08-11 Process for preparing nanometer particle of adriacin-PACA-PBCA

Country Status (2)

Country Link
CN (1) CN1732962A (en)
WO (1) WO2006015534A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115444810B (en) * 2022-04-27 2023-10-13 贵州医科大学 Preparation method of doxorubicin-loaded nanoparticle composite temperature-sensitive gel

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE80468B1 (en) * 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin

Also Published As

Publication number Publication date
WO2006015534A1 (en) 2006-02-16

Similar Documents

Publication Publication Date Title
CN106139144B (en) A kind of hyaluronic acid decorated gold-Nano carbon balls and the preparation method and application thereof with synergistic antitumor characteristic
CN112791185B (en) Nano medicine for treating tumor by combining photo-thermal treatment with iron agent and preparation method thereof
Shao et al. Cascade catalytic nanoplatform based on “butterfly effect” for enhanced immunotherapy
CN102380102A (en) Method for preparing environment-responsive mesoporous silicon nanoparticles
Zhang et al. Tannic acid-assisted synthesis of biodegradable and antibacterial mesoporous organosilica nanoparticles decorated with nanosilver
CN113751079B (en) Perovskite-titanium dioxide nano composite photocatalyst loaded by biological material and construction method and application thereof
CN108354913A (en) A kind of application of nano drug-carrying nanosystems in preparing the drug for treating intractable thyroid cancer
CN113384555A (en) Protein-coated copper-based nanocrystalline drug and preparation method and application thereof
CN110302395B (en) Nanoparticle capable of promoting tumor coagulation and enzyme/pH dual-responsive drug release and preparation method and application thereof
Cai et al. Decorated Au NPs on lignin coated magnetic nanoparticles: Investigation of its catalytic application in the reduction of aromatic nitro compounds and its performance against human lung cancer
Pan et al. pH-responsive glucose-powered Janus polymer brushes nanomotors for drug delivery and controlled release
CN1732962A (en) Process for preparing nanometer particle of adriacin-PACA-PBCA
Gao et al. Multifunctional gold nanoparticles for osteoporosis: synthesis, mechanism and therapeutic applications
CN107929735A (en) A kind of multiple intelligent response microcapsules and its application and preparation method
CN110152021B (en) Drug carrier system with cancer cell internal target administration capability and preparation method thereof
Wang et al. Pulmonary protective effects of ultrasonic green synthesis of gold nanoparticles mediated by pectin on Methotrexate-induced acute lung injury in lung BEAS-2B, WI-38, CCD-19Lu, IMR-90, MRC-5, and HEL 299 cell lines
CN106619568A (en) Preparation method of platinum nanocrystal composite nanomaterial, and product of preparation method
KR20140037290A (en) Agglomerating magnetic alkoxysilane-coated nanoparticles
CN110665005B (en) Iron-doped polymer nanoparticle and preparation method and application thereof
CN112274495B (en) H2O2Preparation method and application of self-supply type calcium peroxide loaded curcumin nanoparticles
CN112402632B (en) Nanoscale coordination polymer for radiotherapy sensitization and preparation method and application thereof
Kar et al. Conclusion and future prospective of silver nanoparticles
Sadeghi et al. Synthesis and characterization of a novel Fe3O4-SiO2@ Gold core-shell biocompatible magnetic nanoparticles for biological and medical applications
Velmathi et al. Biosynthesis of gold nanoparticles by the extremophile bacterium Deinococcus radiodurans and an evaluation of its application in drug delivery
Pang et al. Decorated gold nanoparticles on hydroxymethylated lignin modified magnetic composite: Introducing a novel therapeutic drug for the treatment of renal anemia

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication